News & Events
TEGA Recombinant Heparan Sulfate Inhibits SARS-CoV2
November 12, 2020 - TEGA recombinant heparan sulfate (rHS09) was a potent inhibitor or SARS-CoV2 spike protein binding to human lung cells as published by Jeffrey Esko, Distinguished Professor at the University of California, San Diego and TEGA co-founder, in the journal Cell.
NIH SBIR Phase I Grant Award
July 31, 2019 - TEGA Therapeutics was awarded a phase I SBIR grant from the National Institute of Neurological Disorders and Stroke for the project "Intracerebroventricular alpha-N-acetylglucosaminidase Delivery to the Brain" to develop treatments to alleviate the neurological effects of MPS IIIB.
NSF SBIR Phase I Grant Award
January 31, 2019 - TEGA Therapeutics was awarded a phase I SBIR grant from the National Science Foundation for the project "Bioengineered Recombinant Anticoagulant Heparin" to produce anticoagulant heparin from cultured mammalian cells.
Recombinant Heparin - New Opportunities
December 4, 2018 - Dr. Glass reviews engineering the mammalian heparan sulfate biosynthetic pathway and therapeutic applications for bioengineered heparan sulfate in anticoagulation and beyond.
Link to publication
Metabolic Engineering of Mammalian Cells to Produce Recombinant Heparan Sulfates
August 30, 2018 - Dr. Thacker reviews the progress made to date, opportunities and challenges in manipulating the heparan sulfate biosynthetic pathway to produce bioengineered heparan sulfates.
NIH SBIR Phase I Grant Award
July 20, 2018 - TEGA Therapeutics was awarded a phase I SBIR grant from the National Institute of Neurological Disorders and Stroke for the project "Intracerebroventricular Iduronidase Delivery to the Brain" to investigate treatments to alleviate the neurological effects of MPS I.
TEGA Therapeutics Named a Finalist for 2017 Most Innovative New Product Award
September 18, 2017 - CONNECT, a premier innovation company accelerator in San Diego that creates and scales great companies in the technology and life sciences sectors, announced that TEGA Therapeutics was nominated for the 30th annual Most Innovative New Product Awards. The prestigious awards ceremony is a CONNECT signature event, held annually, that honors San Diego's stars of innovation along with their newly launched groundbreaking products.
Link to press release
Recombinant Heparan Sulfate Product Released
August 1, 2017 - TEGA Therapeutics released its first recombinant heparan sulfate products for distribution to the research community.
NSF STTR Phase I Grant Award
June 20, 2016 - TEGA Therapeutics and Dr. Susan Sharfstein (SUNY Polytechnic Institute) were awarded a phase I STTR grant from the National Science Foundation for the project "Biomanufacture of Novel Heparan Sulfate Glycosaminoglycans" to provide high quality heparan sulfate reagents to the biomedical research community.
NIH SBIR Phase I Grant Award
September 14, 2015 - TEGA Therapeutics was awarded a phase I STTR grant from the National Institute of Neurological Disorders and Stroke for the project "Intranasal Sulfamidase Delivery to the Brain" to investigate novel treatments for MPS IIIA.